Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP versus MP: Results from the VISTA trial

European Journal of Haematology, 04/05/2012

The findings demonstrate clinically meaningful, transitory Health–related quality of life (HRQoL) decrements with bortezomib–melphalan–prednisone (VMP) and relatively lower HRQoL versus melphalan–prednisone (MP) during early treatment cycles, associated with the expected additional toxicities. However, HRQoL is not compromised in the long–term, recovering by the end–of–treatment visit to be comparable versus MP.

Print Article Summary Cat 2 CME Report